文献

J-GLOBAL ID：201902251547628220   整理番号：19A1171156

少なくとも2つの先行化学療法レジメンに抵抗性または不耐性の胃または胃食道接合部癌患者に対するニボルマブのランダム化二重盲検プラセボ対照第三相試験における日本人患者のサブ分析(ONO-4538-12,ATTRACTION-2)

A subanalysis of Japanese patients in a randomized, double-blind, placebo-controlled, phase 3 trial of nivolumab for patients with advanced gastric or gastro-esophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2)

著者 (36件)： Kato Ken (Division of Gastrointestinal Medical Oncology, National Cancer Center Hospital, Tokyo, Japan) ,  Satoh Taroh (Department of Frontier Science for Cancer and Chemotherapy, Osaka University Graduate School of Medicine, Suita, Japan) ,  Muro Kei (Department of Clinical Oncology, Aichi Cancer Center Hospital, Nagoya, Japan) ,  Yoshikawa Takaki (Department of Gastrointestinal Surgery, Kanagawa Cancer Center, Yokohama, Japan) ,  Yoshikawa Takaki (Division of Gastrointestinal Medical Oncology, National Cancer Center Hospital, Tokyo, Japan) ,  Tamura Takao (Department of Medical Oncology, Kindai University, Faculty of Medicine, Osaka, Japan) ,  Tamura Takao (Department of Medical Oncology, Kindai University Nara Hospital, Ikoma, Japan) ,  Hamamoto Yasuo (Keio Cancer Center, School of Medicine, Keio University, Tokyo, Japan) ,  Chin Keisho (Department of Gastroenterology, Cancer Institute Hospital of the Japanese Foundation for Cancer Research, Tokyo, Japan) ,  Minashi Keiko (Clinical Trial Promotion Department, Chiba Cancer Center, Chiba, Japan) ,  Tsuda Masahiro (Department of Gastroenterological Oncology, Hyogo Cancer Center, Akashi, Japan) ,  Yamaguchi Kensei (Department of Gastroenterology, Saitama Cancer Center, Saitama, Japan) ,  Yamaguchi Kensei (Department of Gastroenterology, Cancer Institute Hospital of the Japanese Foundation for Cancer Research, Tokyo, Japan) ,  Machida Nozomu (Division of Gastrointestinal Oncology, Shizuoka Cancer Center, Shizuoka, Japan) ,  Esaki Taito (Department of Gastrointestinal and Medical Oncology, National Hospital Organization Kyushu Cancer Center, Fukuoka, Japan) ,  Goto Masahiro (Cancer Chemotherapy Center, Osaka Medical College Hospital, Takatsuki, Japan) ,  Komatsu Yoshito (Division of Cancer Chemotherapy, Hokkaido University Hospital Cancer Center, Sapporo, Japan) ,  Nakajima Takako Eguchi (Department of Clinical Oncology, St. Marianna University School of Medicine, Kawasaki, Japan) ,  Sugimoto Naotoshi (Department of Medical Oncology, Osaka International Cancer Institute, Osaka, Japan) ,  Yoshida Kazuhiro (Department of Surgical Oncology, Gifu University Graduate School of Medicine, Gifu, Japan) ,  Oki Eiji (Department of Surgery and Science, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan) ,  Nishina Tomohiro (Department of Gastrointestinal Medical Oncology, National Hospital Organization Shikoku Cancer Center, Matsuyama, Japan) ,  Tsuji Akihito (Department of Medical Oncology, Kobe City Medical Center General Hospital, Kobe, Japan) ,  Tsuji Akihito (Department of Medical Oncology, Kagawa University, Takamatsu, Japan) ,  Fujii Hirofumi (Department of Clinical Oncology, Cancer Center Jichi Medical University Hospital, Shimotsuke, Japan) ,  Kunieda Kenji (Department of Medical Oncology, Saku Central Hospital Advanced Care Center, Saku, Japan) ,  Saitoh Soh (Internal Medicine, Misawa City Hospital, Misawa, Japan) ,  Omuro Yasushi (Department of Medical Oncology, Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital, Tokyo, Japan) ,  Azuma Mizutomo (Department of Gastroenterology, Kitasato University School of Medicine, Sagamihara, Japan) ,  Iwamoto Yasuo (Medical Oncology, Hiroshima City Hiroshima Citizens Hospital, Hiroshima, Japan) ,  Taku Keisei (Medical Oncology, Shizuoka General Hospital, Shizuoka, Japan) ,  Fushida Sachio (Gastroenterological Surgery, Kanazawa University Hospital, Kanazawa, Japan) ,  Chen Li-Tzong (National Institute of Cancer Research, National Health Research Institutes, Tainan, Taiwan, Republic of China) ,  Chen Li-Tzong (Department of Internal Medicine, National Cheng Kung University Hospital, National Cheng Kung University, Tainan, Taiwan, Republic of China) ,  Kang Yoon-Koo (Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea) ,  Boku Narikazu (Division of Gastrointestinal Medical Oncology, National Cancer Center Hospital, Tokyo, Japan)
資料名： Gastric Cancer (Web)  (Gastric Cancer (Web))
巻： 22  号： 2  ページ： 344-354  発行年： 2019年 
JST資料番号： U0618A  ISSN： 1436-3291  資料種別： 逐次刊行物 (A)
記事区分： 原著論文  発行国： ドイツ (DEU)  言語： 英語 (EN)

抄録/ポイント： 背景:抗programmed death-1薬ニボルマブは胃...

シソーラス用語： ヒト ,...
準シソーラス用語： *ニボルマブ ,...

ログイン（無料）して見る     続きはJDreamIII（有料）にて  {{ this.onShowAbsJLink("http://jdream3.com/lp/jglobal/index.html?docNo=19A1171156&from=J-GLOBAL&jstjournalNo=U0618A") }}

著者キーワード (4件)： 胃癌 ,  胃食道接合部癌 ,  日本 ,  ニボルマブ

分類 (3件)： 消化器の腫よう  (GH04000D) ,  腫ようの薬物療法  (GE03032C) ,  抗腫よう薬の臨床への応用  (GW16020L)

タイトルに関連する用語 (18件)： 化学療法 ,  レジメン ,  抵抗性 ,  耐性 ,  胃 ,  胃食道接合部 ,  癌患者 ,  ニボルマブ ,  ランダム化 ,  二重盲検 ,  プラセボ ,  対照 ,  第三相試験 ,  日本人 ,  患者 ,  サブ ,  分析 ,  ONO-4538